2. Signaling Pathways
  3. JAK/STAT Signaling
    Stem Cell/Wnt
  4. STAT
  5. STAT6 Isoform
  6. STAT6 Inhibitor

STAT6 Inhibitor

STAT6 Inhibitors (23):

Cat. No. Product Name Effect Purity
  • HY-100614
    AS1517499
    		Inhibitor 99.17%
    AS1517499 is a potent and brain-permeable STAT6 phosphorylation inhibitor with an IC50 of 21 nM.
  • HY-100754
    Ritlecitinib
    		Inhibitor 99.80%
    Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
  • HY-134771
    YM-341619
    		Inhibitor 98.01%
    YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 (IC50=0.28 nM) without affecting Th1 cell differentiation. YM-341619 is a promising compound for the the research of allergic diseases, such as allergic asthma.
  • HY-176949
    STAT6-IN-10
    		Inhibitor 98.81%
    STAT6-IN-10 is a STAT6 (signal transducer and activator of transcription 6) inhibitor with an EC50 of 2 nM. STAT6-IN-10 can inhibit the secretion of CCL17 in human peripheral whole blood. STAT6-IN-10 can be used in the research of dermatological and respiratory system diseases.
  • HY-206870
    BP79
    		Inhibitor
    BP79 is a potent TSLP receptor inhibitor. BP79 disrupts TSLP-mediated ternary complex formation, blocks TSLPR-IL7Rα co-localization, binds and stabilizes TSLPR, and inhibits phosphorylated STAT3/6. BP79 suppresses immune cell infiltration, secretion of IL-13, IL-4. BP79 can be used for the research of inflammation diseases, such as atopic dermatitis, allergic asthma, and allergic rhinitis.
  • HY-182359
    YYSW001
    		Inhibitor
    YYSW001 is a selective and orally acrive JAK1 inhibitor with an IC50 of 6 nM and a Kd of 32.32 μM. YYSW001 blocks JAK1-dependent phosphorylation of STAT6, as well as IL-6-induced phosphorylation of STAT3. YYSW001 suppresses pro-inflammatory cytokine levels, reduces paw swelling, lowers clinical arthritis scores, alleviates joint damage and decreases bone loss. YYSW001 is applicable for the research of rheumatoid arthritis.
  • HY-P990093
    Stapokibart
    		Inhibitor 99.37%
    Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis).
  • HY-158399
    STAT6-IN-5
    		Inhibitor 99.88%
    STAT6-IN-5 (compound 84) is a STAT6 inhibitor (IC50=0.24 μM), which can be used for the research of inflammatory diseases and allergic diseases (e.g. atopic dermatitis).
  • HY-158398
    STAT6-IN-4
    		Inhibitor 99.77%
    STAT6-IN-4 (Ex. 78) is a STAT6 inhibitor, with an IC50 of 0.34 μM. STAT6-IN-4 can be used in the research of diseases such as inflammatory and allergic diseases.
  • HY-134772
    AS1810722
    		Inhibitor 98.10%
    AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.
  • HY-173236
    STAT4-IN-1
    		Inhibitor 99.17%
    STAT4-IN-1 is an inhibitor of STAT4 with a Ki of 0.35 μM. STAT4-IN-1 is expected to be used in the research of autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes.
  • HY-N0407
    Picroside I
    		Inhibitor 99.48%
    Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ.
  • HY-117548
    UNC1062
    		Inhibitor 98.92%
    UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis.
  • HY-100754C
    Ritlecitinib tosylate
    		Inhibitor 99.65%
    Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
  • HY-112961
    Patiromer
    		Inhibitor
    Patiromer is an orally active, selective and non-absorbable intestinal potassium (K+) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.
  • HY-113509B
    15(R)-Lipoxin A4
    		Inhibitor 98.3%
    15 (R)-Lipoxin A4 (15-epi-LXA4) is a specialized pro-resolving mediator and an acetylated derivative of COX2. 15 (R)-Lipoxin A4 is present in neurons. 15 (R)-Lipoxin A4 induces the SPM synthases ALOX12 and ALOX15, as well as the pro-resolving receptor ALX. 15 (R)-Lipoxin A4 inhibits protein kinases, including JNK1/2/3, Lyn, STAT-3 and STAT-6. 15 (R)-Lipoxin A4 enhances the release of pro-resolving mediators. 15 (R)-Lipoxin A4 alleviates the pro-inflammatory phenotype of tendon-derived stromal cells. 15 (R)-Lipoxin A4 promotes the resolution of neuroinflammation. 15 (R)-Lipoxin A4 is applicable to research related to achilles tendinitis, achilles tendon rupture and Alzheimer’s disease.
  • HY-100754A
    Ritlecitinib malonate
    		Inhibitor
    Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
  • HY-162404
    (14S,15R)-14-Deoxyoxacyclododecindione
    		Inhibitor
    (14S,15R)-14-Deoxyoxacyclododecindione (Compound 3) acts as an inhibitor of TGF-β-dependent Smad2/3 and IL-4-dependent STAT6, with IC50 values of 90 nM and 20 nM, respectively. (14S,15R)-14-deoxyoxacyclododecindione is a potent IL-4 inhibitor with an IC50
    value of 20 nM. (14S,15R)-14-Deoxyoxacyclododecindione is applicable to the research of chronic inflammation and fibrotic diseases.
  • HY-W1113771
    STAT6-IN-7
    		Inhibitor 99.53%
    STAT6-IN-7 is a STAT6 inhibitor. STAT6-IN-7 exhibits an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. STAT6-IN-7 can be used in the research of atopic dermatitis.
  • HY-W1113770
    STAT6-IN-8
    		Inhibitor
    STAT6-IN-8 (Compound 9) is a STAT6 inhibitor with potential anti-inflammatory and anti-allergic effects. STAT6-IN-8 can be used for the study of STAT6-associated diseases, including inflammatory diseases (atopic dermatitis, bronchial asthma) and allergic diseases (allergic rhinitis, chronic sinusitis).